Boutique Venture Partners

The Top 25 Healthcare Investors of 2024 GrowthCap is pleased to announce The Top 25 Healthcare Investors of 2024. In our fourth year running this awards process, we continue to be amazed by the caliber of the nominees and the professional accomplishments they have achieved. Healthcare is integral to the quality of our lives and is the foundation for all business and economic activity to occur. Please join us in recognizing and celebrating the achievements of The Top 25 Healthcare Investors of 2024. Jeff Crisan (Silversmith Capital Partners), John Maldonado (Advent International), Jeff Haywood and Steve LeSieur (Spectrum Equity), David Schuppan (The Vistria Group), Andrew Adams (Oak HC/FT), Garheng Kong (HealthQuest Capital), Dr. Robert Mittendorff, MD (B Capital ), Joshua Nelson (THL Partners), Katherine Wood and Kendall Garrison (TPG), Andrew Kaplan (Bain Capital), Mike Kirkman (Blackstone), Carmine Petrone (Advent International), Rob Heimann (RC Capital), Ross Stern (Summit Partners), Laura Veroneau (Optum Ventures), Matt Emery (JMI Equity), Scott Barclay (Insight Partners), David Schulte (McKesson Ventures), Arsani William (Logos Capital), Brian Peterson (Silversmith Capital Partners), William Dai (ShangBay Capital), Dr. Rami El Assal (Boutique Venture Partners), and Aaron Newman (Brighton Park Capital). Nominate Top Private Equity Firms of 2024 at https://lnkd.in/g9hfKiY https://lnkd.in/gaVUV4Qa #leadership #healthcare #investors #firms

Genalyte has received the FIRST FDA clearance for a rapid, quantitative Immunoassay test performed on a silicon chip! 🎉 This Thyroid Stimulating Hormone (TSH) assay is a monumental step forward for us and the entire diagnostic industry. With this breakthrough, TSH testing can now be done in approximately 30 minutes, compared to the traditional 2-5 days. This means faster diagnosis and quicker treatment for the 10% of Americans affected by hypothyroidism. Our revolutionary Maverick system, weighing only 30 lbs and the size of a small microwave, delivers central lab quality results and is poised to transform lab care just as silicon chips revolutionized computing. Read the full press release here: https://lnkd.in/gd9Vdzy9 #FDAcleared #Immunoassay #BloodTest #Diagnostics

I am very excited to share that Surge just secured €7.5 million in our latest fundraising round, to transform precision medicine by decrypting the immune system! This round, led by Eurazeo and joined by Kima Ventures, Teampact.ventures, MH Innov’, along with the continued support from Boutique Venture Partners, HCVC, 50 Partners Health, and business angels like Yann Fleureau means a robust vote of confidence in our vision to revolutionize personalized care. This funding round will provide us with the resources needed to fine-tune our technology and make an impact on healthcare. I couldn't be more proud to lead SurgeCare as we are on the brink of a new chapter, one where our unique approach to precision medicine will touch the lives of thousands of patients. We are now set to advance our initiatives into their next phases of development. With the launch of our first product, PreCyte®, for predicting the risk of postoperative complications, and our premier laboratory, SurgeLab™, for acquiring individualized immune signatures, Surge aims to become a leader in precision immune analysis. A heartfelt thank you to our incredible team, investors, and partners for their unwavering support throughout this journey. We couldn't have done it without each and every one of you. Together, let’s unlock the secrets of the immune system, paving the way for a more personalized and effective medicine than ever before!